Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880651 | 1.00 | CTRB1 (0.49) | CTRB1ITGB3ITGA2BCTSCDPP4 | |
| SCHEMBL14906464 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL6880524 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL6878588 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL6876472 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL6876603 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL18155562 | 0.91 | CTRB1 (0.48) | CTRB1ITGB3ITGA2BCTSCDPP4 | |
| SCHEMBL14906471 | 0.91 | CTRB1 (0.48) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL14903406 | 0.90 | CTRB1 (0.47) | CTRB1CTSCDPP4RENACE | |
| SCHEMBL6880163 | 0.89 | REN (0.51) | CTRB1CTSCREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| EP-2536732-B1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP Z O O (PL) | 2016-10-19 | — | — | EP | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-20130224232-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2013-08-29 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
| WO-2011103524-A2 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP.Z.O.O. (PL) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | CTRB1 1251/4885ITGB3 3077/4885ITGA2B 3551/4885 |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | CTRB1 1251/4885ITGB3 3077/4885ITGA2B 3551/4885 |
| US-20130224232-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, VIP, APLNR | CTRB1 956/4885ITGB3 2617/4885ITGA2B 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.